Jpmorgan Chase & CO Acurx Pharmaceuticals, Inc. Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Acurx Pharmaceuticals, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 29 shares of ACXP stock, worth $10. This represents 0.0% of its overall portfolio holdings.
Number of Shares
29Holding current value
$10% of portfolio
0.0%Shares
3 transactions
Others Institutions Holding ACXP
# of Institutions
27Shares Held
3.49MCall Options Held
100Put Options Held
0-
Sabby Management, LLC Upper Saddle River, NJ2.04MShares$715,5916.36% of portfolio
-
Vanguard Group Inc Valley Forge, PA529KShares$185,2720.0% of portfolio
-
Prospect Financial Services LLC Melville, NY367KShares$128,3010.08% of portfolio
-
Geode Capital Management, LLC Boston, MA171KShares$60,0200.0% of portfolio
-
Morgan Stanley New York, NY106KShares$37,1700.0% of portfolio
About Acurx Pharmaceuticals, Inc.
- Ticker ACXP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,556,600
- Market Cap $4.04M
- Description
- Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The com...